There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Lisata Therapeutics (LSTA – Research Report) and Bolt Biotherapeutics (BOLT – Research Report) with bullish sentiments.
Lisata Therapeutics (LSTA)
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Lisata Therapeutics, with a price target of $15.00. The company’s shares closed last Thursday at $3.70, close to its 52-week low of $3.50.
According to TipRanks.com, Pantginis has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Lisata Therapeutics is a Moderate Buy with an average price target of $15.00.
See Insiders’ Hot Stocks on TipRanks >>
Bolt Biotherapeutics (BOLT)
In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Bolt Biotherapeutics, with a price target of $8.00. The company’s shares closed last Thursday at $1.29, close to its 52-week low of $1.25.
According to TipRanks.com, White is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bolt Biotherapeutics with a $8.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on LSTA:
- Analysts’ Top Technology Picks: Lightpath Technologies (LPTH), Compass (COMP)
- Microsoft (NASDAQ:MSFT) is Alabama Senator’s Favorite Tech Pick
- Leaf Mobile Inc (EAGRF) Receives a Buy from H.C. Wainwright
- H.C. Wainwright Reaffirms Their Buy Rating on Mogo Finance Technology (MOGO)
- aTyr Pharma (LIFE) Receives a Buy from H.C. Wainwright